

Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Primary IR Contact

Melissa Lueke
Executive Vice President
Chief Financial Officer
Meridian Bioscience, Inc.

Stock Performance

VIVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$15.57
Change (%)	▲ 0.01 (0.06%)
Volume	208,877
52 Week Low	\$13.53
Market Cap	\$660,095,164
Rolling EPS	0.53
PE Ratio	29.3314
Shares Outstanding	42,395,322

Data as of 10/19/18 4:00 p.m. ET



Recent Press Releases

- 10/17/2018
Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018
- 10/9/2018
DiaSorin and Meridian Enter Into a Strategic Collaboration to Sell Helicobacter Pylori Stool Antigen Test in the United States and in the United Kingdom
- 9/24/2018
Meridian Bioscience Announces Retirement of John A. Kraeutler, Executive Chairman of the Board; Appoints David C. Phillips as Chairman of the Board; and Elects Felicia Williams to the Board of Directors
- 7/31/2018
Meridian Bioscience Reports Third Quarter 2018 Operating Results, Declares Regular Third Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
- 6/28/2018
Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal Year 2018 Operating Results on Tuesday, July 31, 2018


Upcoming Events

Date	Title
11/08/18 9:00 a.m. ET	Q4 2018 Meridian Bioscience, Inc. Earnings Conference Call

Recent SEC Filings

Filing Date	Form	Description
10/04/18	4	Statement of changes in beneficial ownership of securities
09/24/18	4	Statement of changes in beneficial ownership of securities
09/24/18	8-K	Report of unscheduled material events or corporate event
09/24/18	3	Initial filing by director officer or owner of more than ten percent.

Analyst Estimates / Ratings



Unable to fulfill request.

Management

John A. Kraeutler
Executive Chairman

Jack P. Kenny
Chief Executive Officer

Lawrence J. Baldini
Executive Vice President, Global Operations

Melissa A. Lueke
Executive Vice President, Chief Financial Officer

Susan D. Rolih
Executive Vice President, Regulatory Affairs and Quality Assurance

Lourdes G. Weltzien
Executive Vice President, Life Science

Board of Directors

John A. Kraeutler
Executive Chairman

Jack Kenny
Chief Executive Officer

James M. Anderson
Retired President and Chief Executive Officer Cincinnati Children's Hospital Medical Center

Dwight E. Ellingwood
President, D.E.E. Strategy Consulting, LLC

David C. Phillips
Co-founder Cincinnati Works, Inc

John C. McIlwraith
Co-founder Allos Ventures

John M. Rice
Founder and Managing Partner of Triathlon Medical Venture Partners

Catherine A. Sazdanoff
Chief Business Officer of Strata Oncology, Inc

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	266	628.24	93.7	39,731,118
Mutual Fund	334	351.18	54.5	23,098,287
Insider *	16	15.44	2.4	1,035,675

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	5,558,639	13.1	479,156	06/30/18
The Vanguard Group, Inc.	4,253,779	10.0	60,434	06/30/18
Brown Capital Management, LLC	3,663,919	8.6	-344,320	06/30/18
Renaissance Technologies LLC	2,631,276	6.2	220,500	06/30/18
Dimensional Fund Advisors, L.P.	1,828,334	4.3	9,714	06/30/18
State Street Global Advisors (US)	1,249,154	3.0	82,698	06/30/18
Norges Bank Investment Management (NBIM)	1,136,022	2.7	0	12/31/17
Systematic Financial Management, L.P.	1,131,715	2.7	114,687	06/30/18
M & G Investment Management Ltd.	1,042,600	2.5	0	06/30/18
Geode Capital Management, L.L.C.	808,021	1.9	70,383	06/30/18

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed